Endometrial Cancer Clinical Trials in Oklahoma City, Oklahoma

17 studies are recruiting for endometrial cancer in Oklahoma City, Oklahoma right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

   The study is divided into two cohorts (Cohort 1 and Cohort 2), to which participants will be enrolled based on the amount of human epidermal growth factor receptor 2 (HER2) in their tumor sample. In Cohort 1, the main goal is to assess how well BNT323 (also known as DB-1303) or chemotherapy (doxoru…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Peggy & Charles Stephenson Oklahoma Cancer Center, Oklahoma City, Oklahoma

   Locations

   191 in total

   Run by

   BioNTech SE

   See if you can join NCT06340568 on ClinicalTrials.gov

2. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   University of Oklahoma, Oklahoma City, Oklahoma

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

3. Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

   This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies * EN10.A/RAINBO BLUE: POLE-mutated EC * EN10.B/TAPER: p53 wildtype / N…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

   Locations

   121 in total

   Run by

   Canadian Cancer Trials Group

   See if you can join NCT05640999 on ClinicalTrials.gov

4. Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

   The main purpose of this study is to: * Learn about the safety of ubamatamab and to find out what dose of ubamatamab can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus * The study will also look at the levels of ubamatamab and/or cemiplimab in the body and…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Stephenson Cancer Center, Oklahoma City, Oklahoma

   Locations

   53 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT03564340 on ClinicalTrials.gov

5. DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

   DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participant…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Oklahoma City, Oklahoma

   Locations

   255 in total

   Run by

   AstraZeneca

   See if you can join NCT06989112 on ClinicalTrials.gov

6. Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

   The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.

   Stage

   Phase 1

   Ages

   15 and older

   Site

   OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma

   Locations

   22 in total

   Run by

   Xencor, Inc.

   See if you can join NCT06276491 on ClinicalTrials.gov

7. A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

   This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Normunity Investigational Site, Oklahoma City, Oklahoma

   Locations

   18 in total

   Run by

   Normunity AccelCo, Inc.

   See if you can join NCT07182149 on ClinicalTrials.gov

8. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

   This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Oklahoma - Health Sciences Center, Oklahoma City, Oklahoma

   Locations

   66 in total

   Run by

   Genmab

   See if you can join NCT05579366 on ClinicalTrials.gov

9. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

   This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Stephenson Cancer Center, Oklahoma City, Oklahoma

   Locations

   82 in total

   Run by

   Artios Pharma Ltd

   See if you can join NCT04657068 on ClinicalTrials.gov

10. A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

    A Study of Emi-Le in Participants with Solid Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Stephenson Cancer Center Oklahoma University Health, Oklahoma City, Oklahoma

    Locations

    26 in total

    Run by

    Day One Biopharmaceuticals, Inc.

    See if you can join NCT05377996 on ClinicalTrials.gov

11. Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)

    This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a normal course of their medical management or diagnostic work-up for suspected or confirmed cancer.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Mercy Hospital - OKC, Oklahoma City, Oklahoma

    Locations

    8 in total

    Run by

    Elephas

    See if you can join NCT07327489 on ClinicalTrials.gov

12. A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

    This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Oklahoma Health Stephenson Cancer Center, Oklahoma City, Oklahoma

    Locations

    21 in total

    Run by

    Alliance Foundation Trials, LLC.

    See if you can join NCT04486352 on ClinicalTrials.gov

13. A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

    A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dren Investigational Site, Oklahoma City, Oklahoma

    Locations

    10 in total

    Run by

    Dren Bio

    See if you can join NCT06999187 on ClinicalTrials.gov

14. Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

    The purpose of this study is to determine the recommended Phase 2 dose of zanzalintinib when given in combination with paclitaxel in patients with recurrent high-grade uterine cancer. Other objectives include overall safety and tolerability as well as rates of response.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Oklahoma, Oklahoma City, Oklahoma

    Locations

    4 in total

    Run by

    Washington University School of Medicine

    See if you can join NCT06795009 on ClinicalTrials.gov

15. Study of AVZO-021 in Patients With Advanced Solid Tumors

    This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Oklahoma University, Oklahoma City, Oklahoma

    Locations

    13 in total

    Run by

    Avenzo Therapeutics, Inc.

    See if you can join NCT05867251 on ClinicalTrials.gov

16. Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

    A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Oklahoma University Stephenson Cancer Center, Oklahoma City, Oklahoma

    Locations

    9 in total

    Run by

    Aadi Bioscience, Inc.

    See if you can join NCT05997017 on ClinicalTrials.gov

17. A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

    The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.

    Stage

    Phase 2

    Ages

    18 to 70

    Site

    University of Oklahoma, Oklahoma City, Oklahoma

    Locations

    12 in total

    Run by

    Iovance Biotherapeutics, Inc.

    See if you can join NCT06481592 on ClinicalTrials.gov